The relationship of CPE to HIV dementia: Slain by an ugly fact?

Neurology

Volumn 83, Issue 2, 2014, Pages 109-110

  Berger, Joseph R ^a   Clifford, David B ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CLINICAL EFFECTIVENESS; CNS PENETRATION EFFECTIVENESS; CRYPTOCOCCAL MENINGITIS; EDITORIAL; HAZARD RATIO; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NERVOUS SYSTEM INFLAMMATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TOXOPLASMOSIS; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; AIDS DEMENTIA COMPLEX; CENTRAL NERVOUS SYSTEM; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MALE; METABOLISM; PROCEDURES;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CENTRAL NERVOUS SYSTEM; FEMALE; HUMANS; MALE;

EID: 84903940379     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000580     Document Type: Editorial

References (11)

1. Caniglia EC, Cain LE, Justice A, et al. Antiretroviral penetration into the CNS and incidence of AIDSdefining neurologic conditions. Neurology 2014;83: 134-141.
2. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75: 2087-2096.
3. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis 2013;13: 976-986.
4. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virusassociated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997;42: 689-698.
5. Buescher JL, Gross S, Gendelman H, Ikezu T. The neuropathogenesis of HIV-1 infection. In: Portegies P, Berger JR, eds. HIV/AIDS and the Nervous System. Amsterdam: Elsevier; 2007: 45-68.
6. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65: 65-70.
7. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010;202: 1819-1825.
8. Ellis RJ, Letendre S, Vaida F, et al. Randomized trial of central nervous system-targeted antiretrovirals for HIVassociated neurocognitive disorder. Clin Infect Dis 2014; 58: 1015-1022.
9. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24: 1243-1250.
10. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009;23: 1359-1366.
11. Vassallo M, Durant J, Biscay V, et al. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? AIDS 2014;28: 493-501.